UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.70-85

2018

Volltextzugriff (PDF)

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Journal of gastroenterology and hepatology, 2018-01, Vol.33 (1), p.86-98

2018

Volltextzugriff (PDF)

Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines

Journal of viral hepatitis, 2024-11

Wong, Grace Lai‐Hung

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0367 Machine learning-facilitated predictive model for liver-related events in type 2 diabetes mellitus

Gut, 2024-08, Vol.73 (Suppl 2), p.A268-A268

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0348 Secular trends of glycemic control among patients with cirrhosis: a territory-wide cohort study from 2000 to 2023

Gut, 2024-08, Vol.73 (Suppl 2), p.A17-A18

2024

Volltextzugriff (PDF)

Liver Stiffness Measurement: Simplicity is Prerequisite for Reliability

Gastroenterology (New York, N.Y. 1943), 2013, Vol.144 (1), p.243-244

2013

Volltextzugriff (PDF)

IDDF2024-ABS-0397 Safety of stopping non-selective beta-blockers (NSBBs) according to baveno VII consensus in patients with cirrhosis and well-controlled liver disease aetiology

Gut, 2024-08, Vol.73 (Suppl 2), p.A270-A271

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0385 Mortality of cirrhotic patients with hydrothorax over the last two decades

Gut, 2024-08, Vol.73 (Suppl 2), p.A269-A269

2024

Volltextzugriff (PDF)

IDDF2022-ABS-0199 Fast-track HCV clinic for patients with chronic hepatitis C to achieve hepatitis elimination

Gut, 2022-09, Vol.71 (Suppl 2), p.A95-A95

2022

Volltextzugriff (PDF)

IDDF2024-ABS-0124 Cutting-edge deep learning models with domain adaptation outperform traditional methods in predicting liver-related complications in metabolic dysfunction-associated steatotic liver disease

Gut, 2024-08, Vol.73 (Suppl 2), p.A245-A246

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0395 Test-and-treat strategy for helicobacter pylori in direct oral anticoagulants users and the subsequent risk of upper gastrointestinal bleeding: a population-based analysis

Gut, 2024-08, Vol.73 (Suppl 2), p.A13-A15

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0430 Impact of hepatic steatosis on low-density lipoprotein cholesterol response to statins

Gut, 2024-08, Vol.73 (Suppl 2), p.A273-A274

2024

Volltextzugriff (PDF)

Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B

Clinical gastroenterology and hepatology, 2024-08

2024

Volltextzugriff (PDF)

IDDF2024-ABS-0194 Real-world data with pangenotypic direct-acting antivirals: preliminary results of the SVR10K study

Gut, 2024-08, Vol.73 (Suppl 2), p.A254-A254

2024

Volltextzugriff (PDF)

IDDF2023-ABS-0051 Laboratory parameter-based model for predicting hepatic complications in non-alcoholic fatty liver disease: a territory-wide cohort study

Gut, 2023-06, Vol.72 (Suppl 1), p.A146-A148

2023

Volltextzugriff (PDF)

IDDF2023-ABS-0172 Switching to peginterferon for chronic hepatitis b patients with hepatitis B e antigen seroconversion on entecavir – a long term follow-up study

Gut, 2023-06, Vol.72 (Suppl 1), p.A161-A161

2023

Volltextzugriff (PDF)

IDDF2023-ABS-0171 Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care

Gut, 2023-06, Vol.72 (Suppl 1), p.A160-A160

2023

Volltextzugriff (PDF)

Reply to Sun et al

Clinical infectious diseases, 2020-06, Vol.70 (12), p.2748-2749

2020

Volltextzugriff (PDF)

Reply to Hoffmann and Wolf

Clinical infectious diseases, 2021-10, Vol.73 (7), p.e1782-e1783

2021

Volltextzugriff (PDF)

Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study

Clinical gastroenterology and hepatology, 2024-08

2024

Volltextzugriff (PDF)

IDDF2022-ABS-0226 Long-term risk of hepatocellular carcinoma and hepatic decompensation after hepatitis B surface antigen seroclearance: a territory-wide cohort of 9,769 patients

Gut, 2022-09, Vol.71 (Suppl 2), p.A12-A13

2022

Volltextzugriff (PDF)

IDDF2021-ABS-0077 Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment

Gut, 2021-09, Vol.70 (Suppl 2), p.A76-A76

2021

Volltextzugriff (PDF)

IDDF2020-ABS-0200 Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients

Gut, 2020-11, Vol.69 (Suppl 2), p.A12-A13

2020

Volltextzugriff (PDF)

IDDF2021-ABS-0122 No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients

Gut, 2021-09, Vol.70 (Suppl 2), p.A9-A10

2021

Volltextzugriff (PDF)

1 – 25 von 203

Suche als RSS-Feed

Aktive Filter

KollektionIngentaConnect Journals

ThemaScience & Technology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(187)
Mit Volltextzugriff
(173)

Publikationsform

Sprache

Englisch
(195)
Koreanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 1: Definition, risk factors and assessment

The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups

Updated Guidelines for the Prevention and Management of Chronic Hepatitis B—World Health Organization 2024 Compared With China 2022 HBV Guidelines

IDDF2024-ABS-0367 Machine learning-facilitated predictive model for liver-related events in type 2 diabetes mellitus

IDDF2024-ABS-0348 Secular trends of glycemic control among patients with cirrhosis: a territory-wide cohort study from 2000 to 2023

Liver Stiffness Measurement: Simplicity is Prerequisite for Reliability

IDDF2024-ABS-0397 Safety of stopping non-selective beta-blockers (NSBBs) according to baveno VII consensus in patients with cirrhosis and well-controlled liver disease aetiology

IDDF2024-ABS-0385 Mortality of cirrhotic patients with hydrothorax over the last two decades

IDDF2022-ABS-0199 Fast-track HCV clinic for patients with chronic hepatitis C to achieve hepatitis elimination

IDDF2024-ABS-0124 Cutting-edge deep learning models with domain adaptation outperform traditional methods in predicting liver-related complications in metabolic dysfunction-associated steatotic liver disease

IDDF2024-ABS-0395 Test-and-treat strategy for helicobacter pylori in direct oral anticoagulants users and the subsequent risk of upper gastrointestinal bleeding: a population-based analysis

IDDF2024-ABS-0430 Impact of hepatic steatosis on low-density lipoprotein cholesterol response to statins

Role of Early On-Treatment Serum HBV RNA Declines in Predicting Hepatocellular Carcinoma Risk in Patients With Chronic Hepatitis B

IDDF2024-ABS-0194 Real-world data with pangenotypic direct-acting antivirals: preliminary results of the SVR10K study

IDDF2023-ABS-0051 Laboratory parameter-based model for predicting hepatic complications in non-alcoholic fatty liver disease: a territory-wide cohort study

IDDF2023-ABS-0172 Switching to peginterferon for chronic hepatitis b patients with hepatitis B e antigen seroconversion on entecavir – a long term follow-up study

IDDF2023-ABS-0171 Prospective evaluation of a fast-track treatment pathway for patients with chronic hepatitis B under primary care

Reply to Sun et al

Reply to Hoffmann and Wolf

Baseline Viral Load and On-treatment Hepatocellular Carcinoma Risk in Chronic Hepatitis B: A Multinational Cohort Study

IDDF2022-ABS-0226 Long-term risk of hepatocellular carcinoma and hepatic decompensation after hepatitis B surface antigen seroclearance: a territory-wide cohort of 9,769 patients

IDDF2021-ABS-0077 Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment

IDDF2020-ABS-0200 Impact of rising prevalence of metabolic comorbidities on accuracy of hepatocellular carcinoma risk score in chronic hepatitis B patients receiving antiviral therapy: A territory-wide cohort of 31,953 treated patients

IDDF2021-ABS-0122 No association between proton-pump inhibitor use and adverse clinical outcomes of COVID-19: a territory-wide cohort study of 8,675 patients

IDDF2022-ABS-0120 Hepatocyte apoptosis fragment product cytokeratin-18 M30 and non-alcoholic steatohepatitis risk prediction: an international registry study

Aktive Filter

Suchergebnisse filtern